Partenariat public-privé | EPFL Graph Search

Le partenariat public-privé (PPP) est un mode de financement par lequel une autorité publique fait appel à des prestataires privés pour financer et gérer un équipement assurant ou contribuant au service public. Le partenaire privé reçoit en contrepartie un paiement du partenaire public ou des usagers du service qu'il gère. Ce mode de financement est présent dans de nombreux pays sous des formes variées. L'expression « partenariat public-privé » désigne des projets plus récents, dans la lignée des contrats d', en anglais private finance initiative, apparus en Grande-Bretagne depuis 1992 ; contrats dont se sont inspirés de nombreux pays. Un exemple typique de partenariat public-privé consiste pour un entrepreneur privé à construire un hôpital public dont il gérera ensuite les activités non médicales. Une formule soutenue par certaines organisations internationales L'importance de la dette publique dans certains États occidentaux les pousse à se tourner de plus en plus vers

Institutions, Innovation and Public Health

Viviana Carolina Munoz Tellez de Kieffer

This study concerns the economics of innovation in the area of medical innovation -new diagnostics, medicines and vaccines-, and in particular how innovation contributes to meeting public health needs. Significant advances have taken place in medical science and technological innovations to prevent and treat diseases that are associated to the strong research and innovation system characteristic of the biomedical and pharmaceutical industry in developed countries. However, firms are reluctant to mobilize this capacity towards disease areas where there are significant health needs but the market is not profitable. As a result, less socially valuable innovation takes place than would otherwise be desirable. This problem is analysed in this study through institutional analysis, applied to the area of neglected diseases. The term neglected diseases is used to refer to a group of diseases that affect over 1 billion people worldwide, persist under conditions of poverty and are concentrated mainly in developing countries. Previous studies of the problem of the gap of innovation in neglected diseases have focused on identifying the market failures that cause for-profit firms to invest very little in R&D and innovation in neglected diseases, and advance ideas for new or additional incentives that could encourage greater participation of firms in this area, such as guaranteed payments for R&D efforts or new medical products developed. This study takes on a different approach, centred on analyxing the institutional framework in which R&D and innovation dynamics take place. In particular, the study analyses a recent phenomena: the appearance of a new form of institutional experiment - private non-profit entities organized as product development partnerships (PDPs) that act as "system integrators" to leverage the resources and capabilities of a network of public, philanthropic and private sector partners towards R&D in neglected diseases. The study also examines how this novel PDP institution responds to a well-known incentive mechanism in medical innovation - intellectual property rights. The study finds that PDPs respond differently to IPRs than for-profit firms, and this indicates there are variations in the value, use and impact of IPRs under different institutional settings, beyond the firm. Finally, the study analyses the challenges in leveraging traditional medicinal knowledge to address health needs, particularly in developing countries, and finds that as the traditional institutions that have supported traditional medicine are under strain, new institutions are needed to support this knowledge as it becomes fragile and is more likely to suffer from deterioration or even disappearance, as compared to scientific knowledge.

EPFL2015

Towards a more comprehensive analysis of public governance: Deriving legitimacy, efficiency and effectiveness

Eva Lieberherr

In the context of transformation in the governance of public service sectors, performance criteria have mainly focused on efficiency and effectiveness. However, relying on such output oriented performance criteria in public service sectors may lead to inequalities in service provision and a fragmented polity. Moreover, legitimacy is becoming a central concern in the governance of public service sectors due to the increasing involvement of private actors. This paper proposes to add legitimacy to efficiency and effectiveness and to use these as three criteria for analyzing the performance of governance in a public service sector. This paper elaborates the analytic foundations of these three criteria via two theories: governance theory and new institutional economics. The aim is to create an analytical framework through which governance performance in public service sectors can be evaluated in terms of legitimacy, efficiency and effectiveness.

Cambridge University Press

Can medical products be developed on a non-profit basis? Exploring product development partnerships for neglected diseases

Dominique Foray, Patrick Gaulé, Viviana Carolina Munoz Tellez de Kieffer, Fabiana Visentin

Reliance on market forces can lead to underinvestment in social welfare enhancing innovation. The lack of new medical products in the area of neglected diseases is a case in point. R&D for neglected diseases has increased with new funding and collaborations taking place mainly through product development partnerships (PDPs). PDPs are self-governing, private non-profit R&D organizations. In contrast to push and pull instruments designed to address private-sector R&D underinvestment, PDPs have emerged voluntarily to address this public health challenge. In this study we examine how non-profit R&D collaboration for neglected diseases takes place through PDPs. We find that PDPs act as 'system integrators' that leverage the resources and capabilities of a network of public, philanthropic and private-sector partners. This paper contributes to an understanding of R&D in a non-profit context and highlights the importance of collaboration and non-market institutions for promoting innovation where market failures occur.

Oxford University Press2015

Institutions, Innovation and Public Health

Viviana Carolina Munoz Tellez de Kieffer

EPFL2015